Jonathan Weber1, Veeraya K Tanawattanacharoen1, Amy Seagroves1, Mark C Liang1, Christina M Koppin1, Heather M Ross1, Tania A S S Bachega2, Mitchell E Geffner1,3,4, Monica Serrano-Gonzalez3,5, Gagandeep Bhullar1, Mimi S Kim1,4. 1. Center for Endocrinology, Diabetes and Metabolism, Children's Hospital Los Angeles, Los Angeles, California 90027, USA. 2. Laboratory of Hormones and Molecular Genetics-LIM 42, Division of Endocrinology, Clinics Hospital, School of Medicine, São Paulo University, São Paulo 05508-220, Brazil. 3. Keck School of Medicine of University of Southern California, Los Angeles, California 90033, USA. 4. The Saban Research Institute at Children's Hospital Los Angeles, Los Angeles, California 90027, USA. 5. Division of Pediatric Endocrinology, Hasbro Children's Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island 02903, USA.
Abstract
CONTEXT: Youth with classical congenital adrenal hyperplasia (CAH) exhibit abnormal adrenomedullary function with decreased epinephrine levels noted in newborns and young infants. Little is known about how this relates to morbidity during the first year of life. OBJECTIVE: This work aimed to study plasma epinephrine levels in infants with classical CAH and examine the clinical significance of epinephrine deficiency in the first year of life. METHODS: This prospective cohort study comprised participants recruited from a pediatric tertiary care center: 36 infants with classical CAH due to 21-hydroxylase deficiency and 27 age-matched unaffected controls with congenital hypothyroidism. Main outcome measures included plasma epinephrine levels (N = 27), CYP21A2 genotype (N = 15), and incidence of acute illnesses from birth to age 1 year (N = 28). RESULTS: Epinephrine levels in CAH infants independently predicted illness incidence in the first year of life (β = -0.018, R = -0.45, P = .02) and were negatively correlated with 17-hydroxyprogesterone at diagnosis (R = -0.51, P = .007). Infants with salt-wasting CAH exhibited lower epinephrine levels as newborns than simple-virilizing infants (P = .02). CAH patients had lower epinephrine as newborns than did controls (P = .007) and showed decreases in epinephrine from birth to age 1 year (P = .04). Null genotype was associated with lower newborn epinephrine and more illness in the first year of life, compared to less severe mutation categories. CONCLUSION: Lower epinephrine levels are associated with increased risk of illness among CAH infants. While not currently part of clinical standard of care, measuring epinephrine levels and assessing genotype may help predict acute illness in the first year of life.
CONTEXT: Youth with classical congenital adrenal hyperplasia (CAH) exhibit abnormal adrenomedullary function with decreased epinephrine levels noted in newborns and young infants. Little is known about how this relates to morbidity during the first year of life. OBJECTIVE: This work aimed to study plasma epinephrine levels in infants with classical CAH and examine the clinical significance of epinephrine deficiency in the first year of life. METHODS: This prospective cohort study comprised participants recruited from a pediatric tertiary care center: 36 infants with classical CAH due to 21-hydroxylase deficiency and 27 age-matched unaffected controls with congenital hypothyroidism. Main outcome measures included plasma epinephrine levels (N = 27), CYP21A2 genotype (N = 15), and incidence of acute illnesses from birth to age 1 year (N = 28). RESULTS: Epinephrine levels in CAH infants independently predicted illness incidence in the first year of life (β = -0.018, R = -0.45, P = .02) and were negatively correlated with 17-hydroxyprogesterone at diagnosis (R = -0.51, P = .007). Infants with salt-wasting CAH exhibited lower epinephrine levels as newborns than simple-virilizing infants (P = .02). CAH patients had lower epinephrine as newborns than did controls (P = .007) and showed decreases in epinephrine from birth to age 1 year (P = .04). Null genotype was associated with lower newborn epinephrine and more illness in the first year of life, compared to less severe mutation categories. CONCLUSION: Lower epinephrine levels are associated with increased risk of illness among CAH infants. While not currently part of clinical standard of care, measuring epinephrine levels and assessing genotype may help predict acute illness in the first year of life.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Martina Weise; Sarah L Mehlinger; Bart Drinkard; Erin Rawson; Evangelia Charmandari; Mayumi Hiroi; Graeme Eisenhofer; Jack A Yanovski; George P Chrousos; Deborah P Merke Journal: J Clin Endocrinol Metab Date: 2004-02 Impact factor: 5.958
Authors: S Y Pang; M A Wallace; L Hofman; H C Thuline; C Dorche; I C Lyon; R H Dobbins; S Kling; K Fujieda; S Suwa Journal: Pediatrics Date: 1988-06 Impact factor: 7.124
Authors: R Louise Rushworth; Henrik Falhammar; Craig F Munns; Ann M Maguire; David J Torpy Journal: Int J Endocrinol Date: 2016-01-06 Impact factor: 3.257